Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)

Gilead Sciences

Status and phase: Completed; Phase 3

Conditions: Chronic Hepatitis C Virus

Treatments: Drug: LDV/SOF; Drug: RBV

Study type: Interventional

Funder types: Industry

Identifiers

NCT01851330

GS-US-337-0108

Details and patient eligibility

About

This study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) with or without ribavirin (RBV) administered for 8 or 12 weeks in treatment-naive participants with chronic genotype 1 HCV infection.

Enrollment: 647 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18, with chronic genotype 1 HCV infection
• HCV treatment-naive
• HCV RNA > 10,000 IU/mL at screening
• Screening laboratory values within defined thresholds
• Use of two effective contraception methods if female of childbearing potential or sexually active male

Exclusion criteria

• Pregnant or nursing female or male with pregnant female partner
• Presence of cirrhosis
• Coinfection with HIV or hepatitis B virus (HBV)
• Current or prior history of clinical hepatic decompensation
• Chronic use of systemic immunosuppressive agents
• History of clinically significant illness or any other medical disorder that may interfere with subject treatment, assessment or compliance with the protocol

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

647 participants in 3 patient groups

LDV/SOF 8 Week

Experimental group

Description:

Participants will receive LDV/SOF FDC for 8 weeks.

Treatment:

Drug: LDV/SOF

LDV/SOF+RBV 8 Week

Experimental group

Description:

Participants will receive LDV/SOF FDC plus RBV for 8 weeks.

Treatment:

Drug: RBV

Drug: LDV/SOF

LDV/SOF 12 Week

Experimental group

Description:

Participants will receive LDV/SOF FDC for 12 weeks.

Treatment:

Drug: LDV/SOF